↓ Skip to main content

Patients undergoing lymphadenectomy for stage III melanomas of known or unknown primary site do not differ in outcome

Overview of attention for article published in International Journal of Cancer, August 2013
Altmetric Badge

Mentioned by

twitter
2 X users

Citations

dimensions_citation
14 Dimensions

Readers on

mendeley
8 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Patients undergoing lymphadenectomy for stage III melanomas of known or unknown primary site do not differ in outcome
Published in
International Journal of Cancer, August 2013
DOI 10.1002/ijc.28318
Pubmed ID
Authors

Maria Celia Hughes, Annaliesa Wright, Andrew Barbour, Janine Thomas, B. Mark Smithers, Adele C. Green, Kiarash Khosrotehrani

Abstract

The outcome of patients with palpable melanoma metastases in lymph nodes in the presence (metastatic melanoma of known primary site, MKP) or absence (metastatic melanoma of unknown primary site, MUP) of an identifiable primary tumour remains controversial. Some of the previous studies contained large case series that included historical patients. We aimed to compare outcomes of those with MUPs versus MKPs with palpable lymph node invasion, after staging with modern imaging technology. Aprospective study of patients from a single tertiary institution who were undergoing lymph node dissection for palpable metastatic melanoma between 2000 and 2011 was conducted. All patients were ascertained by computerised tomography scanning and most diagnosed after 2004 had positron emission tomography scanning also. Clinicopathological details about the primary melanoma and lymph node dissections were gathered. Factors associated with recurrence and melanoma-specific mortality in those with MKP and with MUP were assessed using univariate and multivariate analyses. Out of 485 patients studied, 82 had MUP and 403 had MKP. Patients were followed up for a median of 17.4 and 19.0 months, for MKP and MUP, respectively. Five-year adjusted melanoma-specific survival was 58% for MUPs versus 49% for MKPs and was not significantly different between the two groups (adjusted Cox proportional Hazard ratio = 0.88 95% confidence interval [0.58, 1.33] p = 0.54). Previously established prognostic factors such as number of positive nodes and extracapsular extension were confirmed in both sets of patients. We conclude that among melanoma patients presenting with clinically detectable nodes, when accurately staged, those without an identifiable primary lesion have similar outcomes to patients with MKP.

X Demographics

X Demographics

The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 8 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 1 13%
Unknown 7 88%

Demographic breakdown

Readers by professional status Count As %
Student > Master 3 38%
Librarian 1 13%
Professor 1 13%
Student > Doctoral Student 1 13%
Student > Ph. D. Student 1 13%
Other 1 13%
Readers by discipline Count As %
Medicine and Dentistry 5 63%
Biochemistry, Genetics and Molecular Biology 1 13%
Neuroscience 1 13%
Nursing and Health Professions 1 13%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 20 June 2013.
All research outputs
#16,699,002
of 24,558,777 outputs
Outputs from International Journal of Cancer
#10,029
of 12,088 outputs
Outputs of similar age
#126,779
of 202,811 outputs
Outputs of similar age from International Journal of Cancer
#57
of 81 outputs
Altmetric has tracked 24,558,777 research outputs across all sources so far. This one is in the 21st percentile – i.e., 21% of other outputs scored the same or lower than it.
So far Altmetric has tracked 12,088 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.8. This one is in the 12th percentile – i.e., 12% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 202,811 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 27th percentile – i.e., 27% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 81 others from the same source and published within six weeks on either side of this one. This one is in the 19th percentile – i.e., 19% of its contemporaries scored the same or lower than it.